Vector Shedding and Blood Biodistribution in Patients with Severe Hemophilia a Following Administration of Valoctocogene Roxaparvovec

被引：0
|
作者：
Clark, Annie
Hammon, Kevin
Sandza, Krystal
Torres, Richard
Koziol, Elli
Holcomb, Jennifer
Kim, Benjamin
Jayaram, Kala
Russell, Chris
Vettermann, Christian
Henshaw, Joshua
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Valoctocogene Roxaparvovec (Roctavian) - A Gene Therapy for Severe Hemophilia A
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1686): : 157 - 158
  • [2] Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
    Oldenburg, Johannes
    Chambost, Herve
    Liu, Hai
    Hawes, Charles
    You, Xiaojun
    Yang, Xinqun
    Newman, Vanessa
    Robinson, Tara M.
    Hatswell, Anthony J.
    Hinds, David
    Santos, Sandra
    Ozelo, Margareth
    ADVANCES IN THERAPY, 2024, 41 (06) : 2267 - 2281
  • [3] IMPACT OF VALOCTOCOGENE ROXAPARVOVEC ON THE ECONOMIC BURDEN OF ADULTS WITH SEVERE HEMOPHILIA A MANAGED WITH PROPHYLAXIS IN THE UNITED STATES
    Wang, T.
    Chen, E.
    Regan, C.
    Cook, K.
    Kirson, N.
    Santos, S.
    Pezalla, E.
    Skinner, M.
    VALUE IN HEALTH, 2023, 26 (12) : S190 - S190
  • [4] Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A
    Pasi, K. John
    Laffan, Michael
    Rangarajan, Savita
    Robinson, Tara M.
    Mitchell, Nina
    Lester, Will
    Symington, Emily
    Madan, Bella
    Yang, Xinqun
    Kim, Benjamin
    Pierce, Glenn F.
    Wong, Wing Yen
    HAEMOPHILIA, 2021, 27 (06) : 947 - 956
  • [5] SAFETY AND EFFICACY OF VALOCTOCOGENE ROXAPARVOVEC GENE TRANSFER FOR SEVERE HEMOPHILIA A: AN UPDATE FROM 4 YEARS AFTER TREATMENT
    Leavitt, Andrew D.
    Mahlangu, Johnny
    Symington, Emily
    Quon, Doris V.
    Giermasz, Adam
    Key, Nigel S.
    Pipe, Steven W.
    Madan, Bella
    Chou, Sheng-Chieh
    Klamroth, Robert
    Mason, Jane
    Peyvandi, Flora
    Yu, Hua
    Robinson, Tara M.
    Ozelo, Margareth C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 72 - 73
  • [6] Achievement of normal factor VIII activity following gene transfer with valoctocogene roxaparvovec (BMN 270): Long-term efficacy and safety results in patients with severe hemophilia A
    Rangarajan, Savita
    Kim, Benjamin
    Lester, Will
    Symington, Emily
    Madan, Bella
    Laffan, Michael
    Tavakkoli, Fatemeh
    Pierce, Glenn
    Wong, Wing Yen
    Pasi, John
    HAEMOPHILIA, 2018, 24 : 65 - 65
  • [7] Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1
    O'Mahony, Brian
    Mahlangu, Johnny
    Peerlinck, Kathelijne
    Wang, Jiaan-Der
    Lowe, Gillian
    Tan, Chee Wee
    Giermasz, Adam
    Tran, Huyen A.
    Khoo, Teh-Liane
    Cockrell, Erin
    Pepperell, Dominic
    Chambost, Herve
    Lopez Fernandez, Maria Fernanda
    Kazmi, Rashid
    Majerus, Elaine
    Skinner, Mark W.
    Klamroth, Robert
    Quinn, Jennifer
    Yu, Hua
    Wong, Wing Yen
    Lawal, Adebayo
    Robinson, Tara M.
    Kim, Benjamin
    BLOOD, 2021, 138
  • [8] Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1
    O'Mahony, Brian
    Dunn, Amy L.
    Leavitt, Andrew D.
    Peyvandi, Flora
    Ozelo, Margareth C.
    Mahlangu, Johnny
    Peerlinck, Kathelijne
    Wang, Jiaan-Der
    Lowe, Gillian C.
    Tan, Chee Wee
    Giermasz, Adam
    Tran, Huyen
    Khoo, Teh -Liane
    Cockrell, Erin
    Pepperell, Dominic
    Chambost, Herve
    Lopez Fernandez, Maria Fernanda
    Kazmi, Rashid
    Majerus, Elaine
    Skinner, Mark W.
    Klamroth, Robert
    Quinn, Jennifer
    Yu, Hua
    Wong, Wing Yen
    Robinson, Tara M.
    Pipe, Steven W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (12) : 3450 - 3462
  • [9] Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience
    Klamroth, Robert
    Gottstein, Saskia
    HAEMOPHILIA, 2024, 30 (05) : 1247 - 1249
  • [10] Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial
    Leavitt, Andrew D.
    Mahlangu, Johnny
    Raheja, Priyanka
    Symington, Emily
    V. Quon, Doris
    Giermasz, Adam
    Fernandez, Maria Fernanda Lopez
    Kenet, Gili
    Lowe, Gillian
    Key, Nigel S.
    Millar, Carolyn M.
    Pipe, Steven W.
    Madan, Bella
    Chou, Sheng-Chieh
    Klamroth, Robert
    Mason, Jane
    Chambost, Herve
    Peyvandi, Flora
    Majerus, Elaine
    Pepperell, Dominic
    Rivat, Christine
    Yu, Hua
    Robinson, Tara M.
    Ozelo, Margareth C.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
12345